SG11202006916SA - Nitrogenated heterocyclic amide compound, and use thereof for medical purposes - Google Patents
Nitrogenated heterocyclic amide compound, and use thereof for medical purposesInfo
- Publication number
- SG11202006916SA SG11202006916SA SG11202006916SA SG11202006916SA SG11202006916SA SG 11202006916S A SG11202006916S A SG 11202006916SA SG 11202006916S A SG11202006916S A SG 11202006916SA SG 11202006916S A SG11202006916S A SG 11202006916SA SG 11202006916S A SG11202006916S A SG 11202006916SA
- Authority
- SG
- Singapore
- Prior art keywords
- amide compound
- medical purposes
- heterocyclic amide
- nitrogenated heterocyclic
- nitrogenated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016328 | 2018-02-01 | ||
| PCT/JP2019/003052 WO2019151274A1 (en) | 2018-02-01 | 2019-01-30 | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006916SA true SG11202006916SA (en) | 2020-08-28 |
Family
ID=67479787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006916SA SG11202006916SA (en) | 2018-02-01 | 2019-01-30 | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10800784B2 (en) |
| EP (1) | EP3747888A4 (en) |
| JP (2) | JP7241556B2 (en) |
| KR (1) | KR20200115566A (en) |
| CN (1) | CN111655692B (en) |
| AR (1) | AR114237A1 (en) |
| AU (1) | AU2019214048B2 (en) |
| BR (1) | BR112020014177A2 (en) |
| CA (1) | CA3090219A1 (en) |
| CL (1) | CL2020002003A1 (en) |
| CO (1) | CO2020009420A2 (en) |
| IL (1) | IL276386B2 (en) |
| MX (1) | MX2020008126A (en) |
| PE (1) | PE20211273A1 (en) |
| PH (1) | PH12020500613A1 (en) |
| SA (1) | SA520412473B1 (en) |
| SG (1) | SG11202006916SA (en) |
| TW (1) | TWI803570B (en) |
| WO (1) | WO2019151274A1 (en) |
| ZA (1) | ZA202004548B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220362215A1 (en) | 2018-09-11 | 2022-11-17 | Japan Tobacco Inc. | Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound |
| CN110407744A (en) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | A kind of synthetic method of 1- (4-aminopyridine -2- base) ethyl ketone |
| WO2021155841A1 (en) | 2020-02-07 | 2021-08-12 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20230025880A1 (en) * | 2020-03-04 | 2023-01-26 | Japan Tobacco Inc. | Fused tricyclic compound and medicinal use thereof |
| CN116368140A (en) * | 2020-09-10 | 2023-06-30 | 加舒布鲁姆生物公司 | Heterocyclic GLP-1 agonists |
| JPWO2023032940A1 (en) | 2021-09-01 | 2023-03-09 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008132162A1 (en) * | 2007-04-26 | 2008-11-06 | Boehringer Ingelheim International Gmbh | 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments |
| PE20090319A1 (en) * | 2007-06-01 | 2009-03-27 | Schering Corp | GAMMA MODULATORS SECRETASA |
| EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| AR074797A1 (en) * | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | FLUORENE COMPOUND, PHARMACEUTICAL COMPOSITIONS, PDHK AND PDHK2 INHIBITORS, TREATMENT METHODS, USES OF THE SAME AND COMMERCIAL KIT |
| WO2013000084A1 (en) * | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013074388A1 (en) * | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| PL2858986T3 (en) * | 2012-06-12 | 2020-03-31 | Chong Kun Dang Pharmaceutical Corp. | Piperidine derivatives as gpr119 agonists |
| CN103570725B (en) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | Piperazidinoltriazole compound as well as preparation method and application thereof |
| PL2975028T3 (en) * | 2013-03-15 | 2018-10-31 | Japan Tobacco, Inc. | Pyrazole-amide compound and medicinal uses therefor |
| TW201536748A (en) * | 2013-07-01 | 2015-10-01 | Japan Tobacco Inc | Fluorene-amide compounds and pharmaceutical use thereof |
| US20150025120A1 (en) | 2013-07-01 | 2015-01-22 | Japan Tobacco Inc. | Pyrazole-alcohol compounds and pharmaceutical use thereof |
| GB201316823D0 (en) | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| CN105814037B (en) * | 2013-12-17 | 2018-11-30 | 默克专利股份公司 | N1- (the fluoro- 2- hydroxy-2-methyl propiono of 3,3,3- tri-)-piperidine derivative of inhibitor as pyruvic dehydrogenase kinase |
| ES2757052T3 (en) | 2015-07-31 | 2020-04-28 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| ES2797301T3 (en) | 2016-03-29 | 2020-12-01 | Merck Patent Gmbh | Piperidinyl-propanone derivatives |
| EP3448850B1 (en) * | 2016-04-28 | 2020-11-04 | Merck Patent GmbH | Piperidinyl derivatives |
| EP3492452B1 (en) * | 2016-07-29 | 2022-08-31 | Japan Tobacco Inc. | Production method for pyrazole-amide compound |
| EP3496716B1 (en) | 2016-08-15 | 2021-11-03 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| CN109803653A (en) | 2016-10-28 | 2019-05-24 | H.隆德贝克有限公司 | Combined therapy including giving Imidazopyrazines ketone |
| MX2019004763A (en) | 2016-10-28 | 2019-07-01 | H Lundbeck As | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders. |
| US20230025880A1 (en) * | 2020-03-04 | 2023-01-26 | Japan Tobacco Inc. | Fused tricyclic compound and medicinal use thereof |
| JPWO2023032940A1 (en) * | 2021-09-01 | 2023-03-09 |
-
2019
- 2019-01-30 WO PCT/JP2019/003052 patent/WO2019151274A1/en active Application Filing
- 2019-01-30 CA CA3090219A patent/CA3090219A1/en active Pending
- 2019-01-30 KR KR1020207024426A patent/KR20200115566A/en not_active Application Discontinuation
- 2019-01-30 BR BR112020014177-1A patent/BR112020014177A2/en unknown
- 2019-01-30 SG SG11202006916SA patent/SG11202006916SA/en unknown
- 2019-01-30 US US16/261,792 patent/US10800784B2/en active Active
- 2019-01-30 CN CN201980010396.9A patent/CN111655692B/en active Active
- 2019-01-30 PE PE2020001125A patent/PE20211273A1/en unknown
- 2019-01-30 JP JP2019013745A patent/JP7241556B2/en active Active
- 2019-01-30 AR ARP190100202A patent/AR114237A1/en unknown
- 2019-01-30 EP EP19747660.9A patent/EP3747888A4/en active Pending
- 2019-01-30 TW TW108103504A patent/TWI803570B/en active
- 2019-01-30 AU AU2019214048A patent/AU2019214048B2/en active Active
- 2019-01-30 MX MX2020008126A patent/MX2020008126A/en unknown
-
2020
- 2020-07-14 PH PH12020500613A patent/PH12020500613A1/en unknown
- 2020-07-21 SA SA520412473A patent/SA520412473B1/en unknown
- 2020-07-22 ZA ZA2020/04548A patent/ZA202004548B/en unknown
- 2020-07-29 IL IL276386A patent/IL276386B2/en unknown
- 2020-07-29 CO CONC2020/0009420A patent/CO2020009420A2/en unknown
- 2020-07-30 CL CL2020002003A patent/CL2020002003A1/en unknown
- 2020-10-08 US US17/065,679 patent/US20210284644A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034806A patent/JP2023071925A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SA520412473B1 (en) | 2023-02-12 |
| US10800784B2 (en) | 2020-10-13 |
| US20210284644A1 (en) | 2021-09-16 |
| EP3747888A4 (en) | 2021-12-15 |
| EP3747888A1 (en) | 2020-12-09 |
| US20200017505A1 (en) | 2020-01-16 |
| AR114237A1 (en) | 2020-08-05 |
| TWI803570B (en) | 2023-06-01 |
| AU2019214048A1 (en) | 2020-06-25 |
| IL276386B2 (en) | 2023-06-01 |
| CL2020002003A1 (en) | 2020-10-23 |
| PE20211273A1 (en) | 2021-07-19 |
| MX2020008126A (en) | 2020-09-18 |
| ZA202004548B (en) | 2021-10-27 |
| JP2023071925A (en) | 2023-05-23 |
| AU2019214048B2 (en) | 2023-03-16 |
| CN111655692B (en) | 2023-10-10 |
| CA3090219A1 (en) | 2019-08-08 |
| RU2020128593A (en) | 2022-03-03 |
| TW201934553A (en) | 2019-09-01 |
| JP7241556B2 (en) | 2023-03-17 |
| PH12020500613A1 (en) | 2021-05-31 |
| CO2020009420A2 (en) | 2020-08-10 |
| JP2019131544A (en) | 2019-08-08 |
| BR112020014177A2 (en) | 2020-12-08 |
| IL276386A (en) | 2020-09-30 |
| KR20200115566A (en) | 2020-10-07 |
| WO2019151274A1 (en) | 2019-08-08 |
| CN111655692A (en) | 2020-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001340B (en) | Heterocyclic compound and use thereof | |
| ZA202004548B (en) | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes | |
| IL288104A (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| ZA202106304B (en) | Heterocyclic compound and use thereof | |
| EP3816153A4 (en) | Heterocyclic compound and use thereof | |
| IL276952A (en) | 2,4-diaminoquinazoline derivatives and medical uses thereof | |
| IL273339A (en) | Griseofulvin compound and pharmaceutical use thereof | |
| EP4006024A4 (en) | Heterocyclic amide compound, preparation method therefor and use thereof | |
| EP3556761A4 (en) | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | |
| IL287026A (en) | Heterocyclic compounds and uses thereof | |
| SG11202010985TA (en) | Heterocyclic derivatives and use thereof | |
| IL276912A (en) | Heterocyclic compound and use thereof | |
| ZA201901543B (en) | Heterocyclic compound, and harmful-arthropod-controlling agent containing same | |
| IL280644A (en) | Magnesium-serinate compound and use thereof | |
| IL276323A (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| IL267937A (en) | Amide compounds and use thereof | |
| SG11202012625PA (en) | N-substituted tetrahydrothienopyridine derivatives and uses thereof | |
| EP3568137A4 (en) | Heterocyclic compounds and use thereof | |
| IL282142A (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| IL283315A (en) | Heterocyclic compounds and medical use thereof | |
| IL275991A (en) | Cyclic amine derivative and medical use thereof | |
| IL283540A (en) | Dock1-inhibiting compound and use thereof |